152 results on '"Maris, J. M."'
Search Results
2. Angiogenesis Inhibitor TNP-470 During Bone Marrow Transplant and in Minimal Residual Disease
3. Multiple Controls of Oxidative Metabolism in Living Tissues as Studied by Phosphorus Magnetic Resonance
4. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1
5. Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients
6. Supplement to: Recent advances in neuroblastoma
7. Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification
8. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
9. Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Childrenʼs Oncology Group
10. Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma
11. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
12. Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma
13. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
14. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
15. Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study.
16. Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study.
17. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
18. The bioenergetics of preservation of limbs before replantation. The rationale for intermediate hypothermia.
19. Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study.
20. Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).
21. A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.
22. Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A
23. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study
24. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066
25. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
26. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study
27. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study
28. Use of a genome-wide linkage screen to identify a hereditary neuroblastoma predisposition locus at chromosome 2p24–23
29. Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project
30. Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification
31. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
32. The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors
33. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study
34. Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG
35. Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium study
36. Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study
37. Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL)
38. A phase II study of 131I-MIBG for refractory neuroblastoma
39. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group (COG)
40. Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children’s Oncology Group study
41. CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data
42. Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors
43. #419 Analysis of BINl, a putative MycN-interacting tumor suppressor, in neuroblastoma
44. #418 TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts
45. #501 Localization of a neuroblastoma (NB) tumor suppressor gene (TSG) locus within chromosome bands 11q13-23
46. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.
47. Defining Why Cancer Develops in Children.
48. A novel human processed gene, DAD-R, maps to 12p12 and is expressed in several organs
49. Human Krueppel-Related 3 (HKR3): a Candidate for the 1p36 Neuroblastoma Tumour Suppressor Gene?
50. Molecular Genetic Analysis of Familial Neuroblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.